Off note, treatment of an ErbB2 driven mouse model with an inhibitor of EZH2 revealed strong synergy with anti-ErbB2 targeted therapy which highlights the importance of EZH2 in several cancers and emphasizes its clinical relevance [76]. Here, ERBB2 is linked to cancer.